<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02612116</url>
  </required_header>
  <id_info>
    <org_study_id>CMUMK202D</org_study_id>
    <nct_id>NCT02612116</nct_id>
  </id_info>
  <brief_title>Comparison of Administration Strategies of Ticagrelor in Patients With Unstable Angina Pectoris, a Pharmacokinetic / Pharmacodynamic Study</brief_title>
  <official_title>The Impact of Administration Strategy of Ticagrelor on Its Pharmacokinetics and Pharmacodynamics in Patients With Unstable Angina Pectoris - a Randomized, Single-center, Open-label Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Collegium Medicum w Bydgoszczy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Collegium Medicum w Bydgoszczy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the differences in pharmacokinetics and&#xD;
      pharmacodynamics of ticagrelor and its active metabolite depending on the strategy of the&#xD;
      drug administration in patients with unstable angina pectoris.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      On the basis of the current guidelines ticagrelor is a recommended antiplatelet agent in&#xD;
      acute coronary syndromes, including unstable angina pectoris.&#xD;
&#xD;
      According to the results of the MOJITO study, performed in patients with ST-elevation&#xD;
      myocardial infarction, the effect of ticagrelor, measured as platelet inhibition, may be&#xD;
      achieved sooner when crushed tablets are administered. Thus, there may be significant&#xD;
      differences in pharmacokinetics and pharmacodynamics of ticagrelor if pulverized drug is&#xD;
      given orally or sublingually when compared with currently used oral administration of&#xD;
      integral tablets.&#xD;
&#xD;
      The study is designed as an open-label, single-center, randomized trial of different&#xD;
      strategies of administration of ticagrelor in patients with unstable angina pectoris. After&#xD;
      enrollment, the participants will be randomized into three arms, each receiving ticagrelor.&#xD;
      The drug will be given in: (1) pulverized tablets administered sublingually, (2) pulverized&#xD;
      tablets administered orally or in (3) integral tablets orally. The time required for&#xD;
      ticagrelor and its active metabolite AR-C124900XX to reach their maximum serum concentration&#xD;
      will be measured as the primary outcome of the study. Moreover, further evaluation of other&#xD;
      parameters including maximum plasma concentration and area under the plasma concentration of&#xD;
      ticagrelor and its active metabolite will be assessed as secondary outcomes. The platelet&#xD;
      reactivity will be measured with the Multiplate Analyzer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to maximum concentration (tmax) for ticagrelor and AR-C124900XX</measure>
    <time_frame>6 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum ticagrelor and AR-C124900XX concentration</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve for ticagrelor (AUC 0-6h)</measure>
    <time_frame>prior to the initial dose and 15 min, 30 min, 45 min, 1, 2, 3, 4, 6 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve for AR-C124900XX (AUC 0-6h)</measure>
    <time_frame>prior to the initial dose and 15 min, 30 min, 45 min, 1, 2, 3, 4, 6 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet reactivity assessed by Multiple Electrode Aggregometry</measure>
    <time_frame>prior to the initial dose and 30min, 1, 2, 3, 4, 6 hours post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Unstable Angina Pectoris</condition>
  <arm_group>
    <arm_group_label>pulverized ticagrelor sublingually</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pulverized ticagrelor 180 mg (Brilique) administered sublingually</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pulverized ticagrelor orally</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pulverized ticagrelor 180 mg (Brilique) administered orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Integral ticagrelor orally</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ticagrelor 180 mg (Brilique) administered orally in integral tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pulverized ticagrelor sublingually</intervention_name>
    <description>Pulverized ticagrelor (180 mg) administered sublingually</description>
    <arm_group_label>pulverized ticagrelor sublingually</arm_group_label>
    <other_name>Brilique</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pulverized ticagrelor orally</intervention_name>
    <description>Pulverized ticagrelor (180 mg) administered orally</description>
    <arm_group_label>pulverized ticagrelor orally</arm_group_label>
    <other_name>Brilique</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Integral ticagrelor</intervention_name>
    <description>Integral ticagrelor (180 mg) administered orally</description>
    <arm_group_label>Integral ticagrelor orally</arm_group_label>
    <other_name>Brilique</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of informed consent prior to any study specific procedures&#xD;
&#xD;
          -  Diagnosis of unstable angina&#xD;
&#xD;
          -  Male or non-pregnant female, aged 18-80 years old&#xD;
&#xD;
          -  Provision of informed consent for angiography and percutaneous coronary intervention&#xD;
             (PCI)&#xD;
&#xD;
          -  GRACE score &lt;140 pts&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  treatment with ticlopidine, clopidogrel, prasugrel or ticagrelor within 14 days before&#xD;
             the study enrollment&#xD;
&#xD;
          -  hypersensitivity to ticagrelor&#xD;
&#xD;
          -  current treatment with oral anticoagulant or chronic therapy with low-molecular-weight&#xD;
             heparin&#xD;
&#xD;
          -  active bleeding&#xD;
&#xD;
          -  history of intracranial hemorrhage&#xD;
&#xD;
          -  recent gastrointestinal bleeding (within 30 days)&#xD;
&#xD;
          -  history of coagulation disorders&#xD;
&#xD;
          -  platelet count less than &lt;100 x10^3/mcl&#xD;
&#xD;
          -  hemoglobin concentration less than 10.0 g/dl&#xD;
&#xD;
          -  history of moderate or severe hepatic impairment&#xD;
&#xD;
          -  history of major surgery or severe trauma (within 3 months)&#xD;
&#xD;
          -  patients considered by the investigator to be at risk of bradycardic events&#xD;
&#xD;
          -  second or third degree atrioventricular block during screening for eligibility&#xD;
&#xD;
          -  history of asthma or severe chronic obstructive pulmonary disease&#xD;
&#xD;
          -  patient requiring dialysis&#xD;
&#xD;
          -  manifest infection or inflammatory state&#xD;
&#xD;
          -  Killip class III or IV during screening for eligibility&#xD;
&#xD;
          -  respiratory failure&#xD;
&#xD;
          -  history of severe chronic heart failure (NYHA class III or IV)&#xD;
&#xD;
          -  concomitant therapy with strong CYP3A inhibitors (ketoconazole, itraconazole,&#xD;
             voriconazole, telithromycin, clarithromycin, nefazadone, ritonavir, saquinavir,&#xD;
             nelfinavir, indinavir, atazanavir) or strong CYP3A inducers (rifampicin, phenytoin,&#xD;
             carbamazepine, dexamethasone, phenobarbital) within 14 days and during study treatment&#xD;
&#xD;
          -  body weight below 50 kg&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacek Kubica, MD., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiology Department, Dr. A. Jurasz University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiology Department, Dr. A. Jurasz University Hospital</name>
      <address>
        <city>Bydgoszcz</city>
        <state>Kujawsko-Pomorskie</state>
        <zip>85-094</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>November 19, 2015</study_first_submitted>
  <study_first_submitted_qc>November 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2015</study_first_posted>
  <last_update_submitted>October 18, 2016</last_update_submitted>
  <last_update_submitted_qc>October 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Collegium Medicum w Bydgoszczy</investigator_affiliation>
    <investigator_full_name>Jacek Kubica</investigator_full_name>
    <investigator_title>Prof. Jacek Kubica, MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Angina, Unstable</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

